유전자 합성(GS) 시장 보고서 : 동향, 예측, 경쟁 분석(-2035년)

Gene Synthesis Market

The future of the global gene synthesis market looks promising with opportunities in the commercial and academic research markets. The global gene synthesis market is expected to reach an estimated $6.2 billion by 2035 from $1.5 billion in 2027 with a CAGR of 16.3% from 2027 to 2035. The major drivers for this market are the increasing demand for synthetic DNA, the rising applications in personalized medicine, and the growing investments in biotech research.

• Lucintel forecasts that, within the type category, below 1000 bp is expected to witness the highest growth over the forecast period due to cheaper and faster outsourcing of short (less than 250 bp) sequences.
• Within the application category, commercial is expected to witness higher growth over the forecast period due to expanding outsourcing of gene synthesis by biotech companies.
• In terms of regions, APAC is expected to witness the highest growth over the forecast period due to the growth of the biotech industry and related companies in the area.

Emerging Trends in Gene Synthesis Market

It is anticipated that between 2025 and 2027, the gene synthesis market will undergo a significant shift from custom laboratories to centralized and software controlled synthesis. Automation and a decrease in sequencing costs along with the predicted increase in demand for engineered biology in the Pharmaceutical, research, diagnostic, Agriculture, and Industrial Biotechnology sectors will drive market growth. Lucintel expects the main competition to be based on the control of turnaround time, accuracy, regulatory compliance, and integrated Design and Manufacturing systems.

• Automation: Automation of liquid handling, cloud workflows, and quality control sequencing is being integrated into high-throughput foundries. Twist Bioscience reported revenue of $296.6 million for the fiscal year 2024, demonstrating a significant growth of the synthetic DNA market. In the next three to five years, automation will reduce the labor-intensive nature of the work and make larger and more extensive construct libraries available.
• AI-enabled Design: Design software is incorporating the ability to screen for manufacturability, expressibility, and risk of supplied sequences prior to synthesis. The 2025 launch of protein design and DNA design models brought increased accessibility to design software. Failed orders will become less likely and the value will shift to design, synthesis, and validation as a service, respectively.
• Longer and Complex Constructs: Customer requests for longer and more complex constructs like Pathways and Libraries continues to increase, while requests for shorter oligos remains static. In 2025, multiple companies started launching multi-kilobase Gene Assembly Kits. Longer and more complex constructs will drive a significant market increase for gene synthesis. This will also generate a demand for higher fidelity and lower error-correction methods.
• Biosecurity: With synthetic DNA reaching more customer segments, the entire International Gene Synthesis Consortium, which represents over 80% of the world's commercial gene synthesis capacity, is implementing sequence screening as a provider. By 2030, procurement, data exchange, and market access will be underpinned by established screening standards.
• Regional Capacity: Reduced reliance on concentrated supply networks is the goal of governments and biomanufacturing investors as they develop domestic capabilities. In 2025, infrastructure funding for the European Chips Act-like biotechnology initiatives and U.S. federal bioeconomy programs gained interest. While regional production will help mitigate supply uncertainty, competitive markets will increase pressure on prices and turn-around-times.

Gene synthesis is transforming from a niche purchasing category to a core element of the bioeconomy. Providers that combine design automation software with machinery will control repeat demand. During expansion of capacities, pricing pressure will persist, while advanced constructs and regulated applications will maintain a premium. Customers will primarily base their assessments of suppliers on data integrity, biosecurity, reliable deliveries, and technical assistance.

Recent Developments in the Gene Synthesis Market

Gene synthesis market activity continues to increase due to declining oligonucleotide prices and the use of AI to assist design. Increasing demand for engineered biology is also a strong driver for capacity planning. Lucintel believes the focus of competition will be on speed of delivery, accuracy of sequences, biosecurity compliance, and ensuring scalable manufacturing, not price. Investment in the market will continue to be selective, and customers from research, agriculture, and pharmaceuticals will drive market differentiation.

• Capacity Expansion: Twist Bioscience reported revenue of $191.7 million for fiscal first-quarter 2025 (February 2025). The strong demand for high throughput DNA libraries and biologics discovery was attributed to opening larger production facilities. This will result in smaller, regional, competitors offering custom sequences and more specialized products.
• Technology Launch: Integrated DNA Technologies (IDT) introduced expanded xGen sequencing and synthetic biology offerings in 2025, creating a demand for more than just traditional plasmid orders. In the next 3-5 years, companies that integrate design software with synthesis, assembly and validation will capture the largest portion of the customer spend.
• Strategic Collaboration: NVIDIA and Illumina partnered in January 2025 to leverage their combined expertise in accelerated computing and generative AI in genomics. Better sequence interpretation will drive more design requests, and companies within the synthesis market must keep pace by offering integrated computational tools.
• Government Oversight: The U.S. aims for 2025 to increase oversight and implementation of the 2022 Executive Order on biotechnology and biomanufacturing, thereby strengthening scrutiny on biotechnology supply chains. This will increase compliance costs for all companies. However, it should increase the market share of companies that have customer verification and sequence-monitoring systems.
• Commercial Consolidation: Thermo Fisher Scientific has a dominant position in the life science tools industry with a $42.9 billion (reported in February 2025) revenue. While this particular case is not a purely gene-synthesis transaction, consolidation, and related procurement options, will drive the smaller competitors out of the industry in the forecast period.

The gene synthesis market will experience growth related to trust and reliance in delivery, and integration with automated biology. The dominant commercial market will continue to be pharmaceutical discovery, while the demand from academia will continue to be cost sensitive. Regional production will increase as customers reduce the risk of cross border trade. Margin share will increase for suppliers with screening, manufacturing and design software.

Strategic Growth Opportunities in the Gene Synthesis Market

The gene synthesis market is entering a new commercial period as companies start shifting their focus from building the first proof-of-concept tools and technologies to industrial solutions. Between the years 2024 and 2026, it is expected that falling costs of DNA, faster software, and more stringent screening will create a demand for consistent and reliable capacity. Lucintel believes that opportunity lies in the synthesis of quality sequences and application economy.

• Therapeutic Construct Services: Custom genes for cell and gene therapy developers can attract a premium over research sequences. In January 2025, the FDA approved more than 40 cellular and gene therapy products. Demand will become more predictable and regulated as developers outsource the optimization and verification of constructs and the documentation of the process.
• Industrial Biotechnology: Beyond the pharmaceutical market, enzyme libraries and pathway assemblies provide additional avenues for growth. In March 2025, Novo Nordisk reported 2024 sales of DKK 290.4 billion, highlighting that investments in biomanufacturing will remain strong. Large-scale programs for the production of specialty chemicals, biomaterials, and fermentation will likely grow.
• Regional Manufacturing: Synthesis and delivery that can be localized will alleviate customs delays and concerns from data governance. In April 2025, the European Union comprised 27 member states and shared biotechnology funding mechanisms. Regional facilities will attract clients if they can meet very short lead times and screening requirements for various jurisdictions.
• Premium Screened Sequences: Security-certified synthesis, audit trails, and detection of prohibited sequences provide a defensible service tier. The International Gene Synthesis Consortium (IGSC) with over 25 members, in June 2025, demonstrated a growing interest in secure biosecurity. With the increasing importance of biosecurity, the pursuit of documented, continuously screened suppliers will become the norm.
• Digital Design Integration: Generating revenue through the integration of digital design and ordering, manufacturing, and quality control via APIs, is possible. In February 2025, NVIDIA reported revenue of $39.3 billion, reflecting growing investment in the advancement of computational biology. Integrated platforms will encapsulate spending on workflow and decrease customer attrition.

In the coming five years, the winning providers will sell workflows instead of individual oligonucleotides. The major revenue streams will shift toward regulated constructs, industrial biology, regional delivery, assurance of screening, and recurring service. Clients will reward providers who decrease design times and document provenance and performance. There will always be a need for a large provider, but smaller providers can protect their margins using application specific libraries and custom synthesis.

Gene Synthesis Market Drivers and Challenges

The gene synthesis market is defined by the dynamics of increasing customization, decreasing costs, and increasingly sophisticated biosecurity measures. Growing demand from pharmaceutical, agricultural, industrial and academic sectors for custom DNA is driven by competing needs to discover and innovate faster. Lucintel predicts that market success will balance innovation with affordability whilst addressing quality, compliance, security and sustainable access in global supply chains.

The factors responsible for driving this market include:

• Customer Demand: Market growth is driven by growing customized gene, DNA library, plasmid, and pathway demand in the areas of drug discovery, diagnostics, agriculture and industrial biotechnology. In January 2025, millions of engineered DNA constructs continued to be used in biological research globally. In the next 3-5 years, market growth is expected to accelerate due to growing demand for outsourced synthesis. This is expected due to the reduced time, lab work, and errors in biological research. Growth is expected to be in the area of more complex constructs, variant libraries, and sequence modalities that facilitate newer and more tailored biological research.
• Technology Advancements: Advancements in automation, artificial intelligence, and high-throughput assembly have made synthesis more precise and more able to produce longer and more complex sequences. By February 2025, most commercial providers started offering modular assembly and quality control workflows for constructs exceeding 100,000 base pairs. In the next three to five years, the market will see the positive effects of advancements in automation and synthetic biology. This will decrease the time it takes to synthesize sequences and make synthetic genomes and constructs for synthetic cells and synthetic pathways. Advancements in software will enable customers to synthesize and track their orders with a unified digital interface.
• Pharmaceutical and Biotechnological Research: The demand for gene synthesis includes the fields of developing vaccines, therapeutics, and engineered biological systems. In March 2025, approximately 2,000 clinical studies for gene therapies and cellular therapies were ongoing around the world. This signifies a long-term demand for research-grade DNA and viral-vector components. In the next three to five years, this will influence the market since pharmaceutical companies will continue to fund the usage of synthetic genes to perform synthetic biology and expedite target validation, protein engineering, and the development of therapeutics with increased efficacy. This will drive an increase in funding for precision medicine, furthering the demand for custom high-quality, sequence-verified biomaterials.
• Sustainability and Bioeconomy Expansion: Synthetic biology offers multiple opportunities for the lower-carbon production of chemicals, materials, fuels and food ingredients as well as agricultural inputs. By April of 2025, bio-based production focused on replacing petroleum-based products across multiple industrial sectors. In the coming three-to-five year period, this trend will affect the market as companies will need to invest in synthetic DNA to engineer microbes and optimize biological production pathways. Manufacturers will make this investment as companies shift toward renewable feedstocks and lower energy consumption, generate less waste, and create more resilient supply chains. In addition, sustainable procurement practices may favor suppliers who use improved synthesis technologies and marginal impact laboratory operations.
• Manufacturing Efficiency and Cost-Advantages: Lowering per base costs and production run consistency is accelerated by larger manufacturing facilities, automation of purification, standardized work flows, and regional fulfillment. By May of 2025, high throughput providers had developed manufacturing systems that automated the processing of thousands of individual DNA orders per day. This trend will affect the market during the coming three-to-five years as gene synthesis services will become available to smaller academic centers and agri-tech companies. This decrease in cost will enable more innovative design approaches, while faster delivery will decrease project completion times. Given these changes, suppliers will need to focus on maintaining product quality.

The challenges facing this market include:

• Biosecurity and Regulatory Compliance: Gene synthesis vendors must screen customer identity, sequence, and review hazardous biological content. Further, they must comply with various laws of different countries. In June 2025, deliberations focused on the harmonization of the screening of synthetic DNA providers across various jurisdictions. This issue will shape the Market in the next 3-5 years, while the Market matures, as the need for more oversight increases the compliance cost and the time to review orders. Effective screening, however, helps to build and maintain public confidence and prevents market misuse. The Market is likely to be dominated by vendors with automated risk assessment systems and secure databases.
• Technical Complexity and Quality Control: The accurate synthesis of long, repetitive, toxic, or GC-rich sequences is challenging and may require succession, assembly, or validation. In July 2025, multiple quality-control checks, including sequencing and restriction analysis, were required for the use of complex constructs in research. In the next 3-5 years, this issue will impact the Market with customer expectation for longer sequences and constructs of complete pathways. Failure to synthesize will increase costs and delay development. Providers must make substantial investments in synthesis, redesign, and assembly, as well as new methods of error correction and instrumentation.
• Supply Chain, Pricing, and Competitive Pressure: Gene synthesis is a complicated process that requires specialized reagents and enzymes, equipment, a workforce, data infrastructure and logistics, and relies on supply chain networks. As of August 2025, laboratories throughout different regions reported significant lead times of weeks for sourcing specific Biotech inputs. Over the next 3-5 years, this is anticipated to stimulate the market as the risk of disruptions, currency shifts, tariffs, and aggressive competing prices brings margins down and unreliable supply. Smaller vendors will struggle to fund advanced automation and quality systems. Regional production, additional vendor sourcing, inventory management, and complex-sequence services will become necessary.

Customized DNA synthesis is expected to increase with the anticipated growth in biotech, pharma, industrial bio, and sustainable business initiatives. Improving technology and manufacturing at scale is expected to decrease the cost and increase the speed and complexity of sequences. However, gene synthesis will likely be limited by biosecurity concerns, disrupted supplies, and competing prices. Offering automation and quality assurance services to clients combined with secure screening and regulations will give providers a competitive edge. The future of the market will depend on sustaining the balance between affordability, safety, and reliability while ensuring responsible access to complex genetic materials for clients of all kinds.

List of Gene Synthesis Market Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies gene synthesis market companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the gene synthesis market companies profiled in this report include-

• GenScript
• Thermo Scientific
• IDT
• Eurofins Genomics
• DNA 2.0
• BBI
• Azenta Life Sciences
• SBS Genetech
• Bio Basic
• Twist Bioscience

Gene Synthesis Market by Segment

The study includes a forecast for the global gene synthesis market by type, application, and region.

Gene Synthesis Market by Type [Value ($B) from 2019 to 2035]:

• Below 1000 bp
• 1001-3000 bp
• 3001-5000 bp
• Above 5000 bp

Gene Synthesis Market by Application [Value ($B) from 2019 to 2035]:

• Commercial
• Academic Research

Gene Synthesis Market by Region [Value ($B) from 2019 to 2035]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Gene Synthesis Market

The gene synthesis market for 2025 to 2027 shows an increase in demand due to biomanufacturing, genomic medicine, and national biotechnology strategies with a more dispersed geographical capacity investment. According to Lucintel's latest market assessment, supplier execution and policy support will remain vital to market development.

• United States: The Federal government supports continued domestic manufacturing with a focus on the All of Us Research Program. In January 2025, the National Institutes of Health indicated that the program had reached 900,000 participants, establishing a stronger foundation for the country's genomic research with Twist Bioscience and Integrated DNA Technologies continuing to fund high-throughput oligonucleotide and gene-production programs. It is anticipated that the investments will sustain buying activity from pharmaceutical, academic, and synthetic-biology clients for the next three to five years.
• China: Local capacities for sequencing and synthesis remain dominant in the national biotechnology priorities. BGI's 2024 report, published in March 2025, indicated that the company generated over RMB3.1 billion in revenue for the year, while GenScript maintained integrated gene, protein, and cell therapy manufacturing. The combination of local suppliers and public sector genomic programs will further support local procurement and lessen the reliance on imported research supplies.
• Germany: Funding for industrial biotechnology and pharmaceutical production is maintained on a pan-European and national level. In February 2025, BioNTech reported €2.75 billion in 2024 revenues and continued spending on the development of its mRNA technology and personalized immunotherapy that requires dedicated DNA constructs. This makes sure that the requirements for compliant and quality manufacturing of DNA synthesis are fulfilled. It secures Germany's position in regulated life-science production within the European Union.
• India: Increasing population genomics infrastructures. January 2025, the Genome India project reportedly made 10,000 genomes project data available to researchers for domestic assay, diagnostic, and research use. This will create demand for synthetic DNA and its associated quality controls.
• Japan: Precision medicine and biopharmaceutical initiatives are continued to be prioritized by the government. March 2025, Takara Bio reported the fiscal year 2025 revenue of ¥46.3 billion with continued investments in DNA and RNA synthesis and gene editing as well as gene manufacturing technologies. It will create an ongoing need for reliable synthesis in academic, diagnostic, and pharmaceutical laboratories.

Features of the Global Gene Synthesis Market

• Market Size Estimates: gene synthesis market size estimation in terms of value ($B).
• Trend and Forecast Analysis: Market trends (2019 to 2026) and forecast (2027 to 2035) by various segments and regions.
• Segmentation Analysis: gene synthesis market size by type, application, and region in terms of value ($B).
• Regional Analysis: gene synthesis market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
• Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the gene synthesis market.
• Strategic Analysis: This includes M&A, new product development, and competitive landscape of the gene synthesis market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the gene synthesis market by type (below 1000 bp, 1001-3000 bp, 3001-5000 bp, and above 5000 bp), application (commercial and academic research), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 7 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

• 2.1 Background and Classifications
• 2.2 Supply Chain

3. Market Trends & Forecast Analysis

• 3.1 Macroeconomic Trends and Forecasts
• 3.2 Industry Drivers and Challenges
• 3.3 PESTLE Analysis
• 3.4 Patent Analysis
• 3.5 Regulatory Environment

4. Global Gene Synthesis Market by Type

• 4.1 Overview
• 4.2 Attractiveness Analysis by Type
• 4.3 Below 1000 bp : Trends and Forecast 2019 to 2035
• 4.4 1001-3000 bp : Trends and Forecast 2019 to 2035
• 4.5 3001-5000 bp : Trends and Forecast 2019 to 2035
• 4.6 Above 5000 bp : Trends and Forecast 2019 to 2035

5. Global Gene Synthesis Market by Application

• 5.1 Overview
• 5.2 Attractiveness Analysis by Application
• 5.3 Commercial : Trends and Forecast 2019 to 2035
• 5.4 Academic Research : Trends and Forecast 2019 to 2035

6. Regional Analysis

• 6.1 Overview
• 6.2 Global Gene Synthesis Market by Region

7. North American Gene Synthesis Market

• 7.1 Overview
• 7.2 North American Gene Synthesis Market by Type
• 7.3 North American Gene Synthesis Market by Application
• 7.4 The United States Gene Synthesis Market
• 7.5 Canadian Gene Synthesis Market
• 7.6 Mexican Gene Synthesis Market

8. European Gene Synthesis Market

• 8.1 Overview
• 8.2 European Gene Synthesis Market by Type
• 8.3 European Gene Synthesis Market by Application
• 8.4 German Gene Synthesis Market
• 8.5 French Gene Synthesis Market
• 8.6 Italian Gene Synthesis Market
• 8.7 Spanish Gene Synthesis Market
• 8.8 The United Kingdom Gene Synthesis Market

9. APAC Gene Synthesis Market

• 9.1 Overview
• 9.2 APAC Gene Synthesis Market by Type
• 9.3 APAC Gene Synthesis Market by Application
• 9.4 Chinese Gene Synthesis Market
• 9.5 Indian Gene Synthesis Market
• 9.6 Japanese Gene Synthesis Market
• 9.7 South Korean Gene Synthesis Market
• 9.8 Indonesian Gene Synthesis Market

10. ROW Gene Synthesis Market

• 10.1 Overview
• 10.2 ROW Gene Synthesis Market by Type
• 10.3 ROW Gene Synthesis Market by Application
• 10.4 Middle Eastern Gene Synthesis Market
• 10.5 South American Gene Synthesis Market
• 10.6 African Gene Synthesis Market

11. Competitor Analysis

• 11.1 Product Portfolio Analysis
• 11.2 Operational Integration
• 11.3 Porter's Five Forces Analysis
  • Competitive Rivalry
  • Bargaining Power of Buyers
  • Bargaining Power of Suppliers
  • Threat of Substitutes
  • Threat of New Entrants
• 11.4 Market Share Analysis

12. Opportunities & Strategic Analysis

• 12.1 Value Chain Analysis
• 12.2 Growth Opportunity Analysis
  • 12.2.1 Growth Opportunity by Type
  • 12.2.2 Growth Opportunity by Application
• 12.3 Emerging Trends in the Global Gene Synthesis Market
• 12.4 Strategic Analysis
  • 12.4.1 New Product Development
  • 12.4.2 Certification and Licensing
  • 12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

13. Company Profiles of the Leading Players Across the Value Chain

• 13.1 Competitive Analysis Overview
• 13.2 GeneScript
  • Company Overview
  • Gene Synthesis Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.3 Thermo Scientific
  • Company Overview
  • Gene Synthesis Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.4 IDT
  • Company Overview
  • Gene Synthesis Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.5 Eurofins Genomics
  • Company Overview
  • Gene Synthesis Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.6 DNA 2.0
  • Company Overview
  • Gene Synthesis Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.7 BBI
  • Company Overview
  • Gene Synthesis Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.8 Azenta Life Sciences
  • Company Overview
  • Gene Synthesis Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.9 SBS Genetech
  • Company Overview
  • Gene Synthesis Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.10 Bio Basic
  • Company Overview
  • Gene Synthesis Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.11 Twist Bioscience
  • Company Overview
  • Gene Synthesis Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing

14. Appendix

• 14.1 List of Figures
• 14.2 List of Tables
• 14.3 Research Methodology
• 14.4 Disclaimer
• 14.5 Copyright
• 14.6 Abbreviations and Technical Units
• 14.7 About Us
• 14.8 Contact Us